Recruiting
Phase 4

Overactive Bladder

Sponsor:

VA Office of Research and Development

Code:

NCT07187466

Conditions

Overactive Bladder

Parkinson Disease

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

mirabegron

Exercise-based behavioral therapy

Study Details

Brief summary:

The purpose of this study is to learn about different treatments for overactive bladder symptoms in Parkinson's Disease. The investigators want to find out if people who do not respond to one treatment (either behavioral or drug treatment) will respond to combined treatment. The investigators also want to find out what factors influence whether someone responds to the treatments.

Conditions

Overactive Bladder

Parkinson Disease

Study ID

NCT07187466

Start date

Nov 9, 2026

Status verified date

Nov, 2026

Completion date

Jun 30, 2030

Anticipated

Primary completion date

Mar 31, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Clinical diagnosis of Parkinson's Disease (PD) determined by a board-certified neurologist with specialty training in movement disorders
  • An Incontinence Questionnaire-Overactive Bladder module (ICIQ-OAB) Symptom Score of 7 or higher, which indicates clinically significant symptoms of overactive bladder (OAB), defined as presence of urinary urgency with or without urgency incontinence usually with increased daytime frequency and nocturia in the absence of infection or other obvious pathology

Exclusion Criteria:

  • Significant cognitive impairment, as indicated by a Montreal Cognitive Assessment (MoCA) score of < 18 or a telephone-MoCA score < 13, which is the recommended diagnostic cut point for dementia in Parkinson's Disease (PD).
  • Previous intensive pelvic floor muscle exercise training
  • Clinically significant depression as measured by a Geriatric Depression Scale-Short Form score of 10 or higher which could affect motivation to fully engage in the intervention
  • Use of an indwelling urinary catheter
  • Post-void residual urine measurement by bladder ultrasound of > 150 milliliters (mL)
  • Severe uterine prolapse past the vaginal introitus
  • Poorly controlled diabetes defined by a hemoglobin A1c (HgbA1c) of >9.0% within the last 3 months. Participants with poorly controlled diabetes will be offered enrollment if the overactive bladder (OAB) symptoms persist after improvement in diabetes control
  • Chronic renal failure and on hemodialysis
  • Genitourinary cancer with ongoing surgical or external beam radiation treatment
  • Previous artificial urinary sphincter, sling procedure or implanted sacral neuromodulation device
  • History of bladder-injection of botulinum toxin in the last 12 months
  • Any unstable health condition expected to result in hospitalization or death within in the next 3 months as determined by principal investigator.
  • Hypersensitivity to drug class
  • Contraindication to the study drug (mirabegron) including history of acute urinary retention requiring catheterization
  • Current use of a bladder relaxant - permitted to enroll after one-week washout
  • Hematuria on microscopic examination in the absence of infection. A urologic consultation will be recommended, and enrollment will depend on clearance by a urologist and agreement by the site PI that entry into the treatment protocol is not contraindicated
  • If on diuretic, dose should be stable for at least 4 weeks
  • If taking an alpha-blocker, dose should be stable for at least 4 weeks
  • If taking dutasteride or finasteride, dose should be stable for at least 6 months

Study Design

Enrollment

146 participants

Anticipated

Allocation

Randomized

Intervention Model

Sequential

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Drug Therapy Group

Participants who are randomized to drug therapy will receive mirabegron 25mg at visit 2 (randomization visit).

active comparator: Behavioral Therapy Group

Participants who are randomized to exercise-based behavioral therapy will receive a comprehensive training program administered individually by a trained nurse practitioner interventionist to address urinary incontinence and other lower urinary tract symptoms.

active comparator: Combined Drug and Behavioral Therapy Group

At 6 weeks post-randomization, participants will complete the ICIQ-OAB questionnaire. Participants reporting less than 3 points reduction will be re-randomized to either continue their initial treatment assignment or receive combination therapy by adding the alternate treatment strategy, thus participants initially treated with mirabegron will add behavioral therapy and participants initially treated with behavioral therapy will add mirabegron.

Interventions

mirabegron

Mirabegron is a beta-3-agonist, which acts upon the noradrenergic system and avoids the cognitive and gastrointestinal side effects of anticholinergic bladder relaxants.

Exercise-based behavioral therapy

The exercise-based behavioral therapy is a comprehensive training program administered individually by a trained nurse practitioner interventionist to address urinary incontinence and other lower urinary tract symptoms.

Primary outcome measure

  • ICIQ-OAB [ Time Frame: baseline, 6-weeks, and 12-weeks ]

Central Contacts and Locations

Central contacts

Locations

Atlanta VA Medical and Rehab Center, Decatur, GA

Recruiting

Decatur, Georgia, United States, 30033-4004

Contacts

Principal Investigator:

Elizabeth Camille Vaughan, MD MS

More Information

Sponsor

VA Office of Research and Development

Last update posted

Nov 17, 2026

Last verified

Nov, 2026

Keywords

  • Urinary Bladder, Overactive
  • Parkinson Disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-18. This information was provided to ClinicalTrials.gov by VA Office of Research and Development on 2026-11-17. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.